OC
CRVS icon

Oppenheimer & Co’s Corvus Pharmaceuticals CRVS Stock Holding History

Oppenheimer & Co’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-22,534
Closed -$71.7K – 1615
2025
Q1 		$71.7K Buy
22,534
+4,490
+25% +$21.1K ﹤0.01% 1531
2024
Q4 		$96.5K Buy
18,044
+1,097
+6% +$8.19K ﹤0.01% 1508
2024
Q3 		$89.5K Buy
+16,947
New +$60.9K ﹤0.01% 1464

Other funds holding CRVS

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
FCMV
Foresite Capital Management VI Larkspur, California $643M AUM 343.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Oppenheimer & Co's CRVS Position: Q2 2025 in Review

Oppenheimer & Co sold out of Corvus Pharmaceuticals (CRVS) in Q2 2025, closing a stake of 22,534 shares — an estimated $71.7K sold.

Oppenheimer & Co first reported a position in CRVS in Q3 2024 and held it in 3 quarters. The position peaked at $96.5K in Q4 2024. 92 funds tracked by Wall St. Rank hold CRVS as of Q2 2025.

  • Oppenheimer & Co reported no remaining Corvus Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Oppenheimer & Co sold 22,534 Corvus Pharmaceuticals shares in Q2 2025, an estimated $71.7K.
  • Oppenheimer & Co first reported a position in Corvus Pharmaceuticals in Q3 2024 and held it in 3 quarters.
  • Oppenheimer & Co's Corvus Pharmaceuticals position peaked at $96.5K in Q4 2024.
  • 92 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2025.

Based on Oppenheimer & Co's 13F filing for Q2 2025, filed 31 Jul 2025.